3 completed, 3 recruiting, 1 terminated. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 3, Recruiting 3, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Left Ventricular Systolic Dysfunction: new trials by email Literature Review of Left Ventricular Systolic Dysfunction trials Research Report on Left Ventricular Systolic Dysfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction Finerenone (Kerendia, BAY94-8862) - Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric) | Phase 3 | Recruiting | Bayer | 117 | 2026-06-01 | 2026-10-27 |
| A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction Finerenone (Kerendia, BAY94-8862), Placebo - Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric) | Phase 3 | Recruiting | Bayer | 111 | 2025-11-19 | 2026-10-15 |
| Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) Vericiguat tablet, Vericiguat suspension, Placebo tablet - Heart Failure, Left Ventricular Systolic Dysfunction | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 342 | 2023-05-31 | 2026-11-13 |
| Ertugliflozin for Functional Mitral Regurgitation Ertugliflozin, Placebo - Mitral Valve Insufficiency, Left Ventricular Systolic Dysfunction | Phase 3 | Completed | Asan Medical Center | 128 | 2020-11-04 | 2025-01-06 |
| Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion Placebos, Dobutamine - Sepsis, Cardiomyopathies | Phase 3 | Completed | University Hospital, Limoges | 136 | 2020-09-20 | 2025-11-21 |
| Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry Linagliptin, Placebo - Diabetes Mellitus, Type 2, Left Ventricular Systolic Dysfunction | Phase 3 | Completed | Heart Care Foundation | 188 | 2015-07-01 | 2021-05-25 |
| STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial G-CSF administration - Anterior Acute Myocardial Infarction, Left Ventricular Systolic Dysfunction | Phase 3 | Terminated | Heart Care Foundation | 532 | 2013-10-01 | 2021-02-03 |
Ventricular Dysfunction, Left (7) · Heart Failure (3) · Cardiomyopathies (1) · Diabetes Mellitus, Type 2 (1) · Mitral Valve Insufficiency (1) · Sepsis (1)
Cardiovascular Diseases (7) · Heart Diseases (7) · Ventricular Dysfunction (7) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Heart Valve Diseases (1) · Infections (1) · Inflammation (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Systemic Inflammatory Response Syndrome (1)
finerenone (2) · Dobutamine (1) · Linagliptin (1) · ertugliflozin (1) · vericiguat (1)
Bayer (2) · Heart Care Foundation (2) · Asan Medical Center (1) · Merck Sharp & Dohme LLC (1) · University Hospital, Limoges (1)
Italy (5) · South Korea (4) · Belgium (3) · Brazil (3) · Canada (3) · Finland (3) · Germany (3) · Hungary (3) · Mexico (3) · Poland (3) · Portugal (3) · Spain (3) · Sweden (3) · Turkey (Türkiye) (3) · United Kingdom (3)
Carlo B. Giorda, MD (1) · Felice Achilli, MD (1) · Giulio Pompilio, MD (1)
PMID 33755143, PMID 38690659, PMID 38916717, PMID 39401872, PMID 40588393